298 related articles for article (PubMed ID: 19877646)
21. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
[TBL] [Abstract][Full Text] [Related]
22. Preparation and antitumour properties of the enantiomers of a hypoxia-selective nitro analogue of the duocarmycins.
Tercel M; Lee HH; Yang S; Liyanage HD; Mehta SY; Boyd PD; Jaiswal JK; Tan KL; Pruijn FB
ChemMedChem; 2011 Oct; 6(10):1860-71. PubMed ID: 21793220
[TBL] [Abstract][Full Text] [Related]
23. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
[TBL] [Abstract][Full Text] [Related]
24. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
[TBL] [Abstract][Full Text] [Related]
25. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
26. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
[TBL] [Abstract][Full Text] [Related]
27. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
Duan JX; Jiao H; Kaizerman J; Stanton T; Evans JW; Lan L; Lorente G; Banica M; Jung D; Wang J; Ma H; Li X; Yang Z; Hoffman RM; Ammons WS; Hart CP; Matteucci M
J Med Chem; 2008 Apr; 51(8):2412-20. PubMed ID: 18257544
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
Kim SY; Rockwell S
Oncol Res; 1995; 7(5):39-47. PubMed ID: 8534933
[TBL] [Abstract][Full Text] [Related]
29. N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs.
Lu GL; Stevenson RJ; Chang JY; Brothers PJ; Ware DC; Wilson WR; Denny WA; Tercel M
Bioorg Med Chem; 2011 Aug; 19(16):4861-7. PubMed ID: 21775153
[TBL] [Abstract][Full Text] [Related]
30. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
31. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
32. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM
Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580
[TBL] [Abstract][Full Text] [Related]
33. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
Günther M; Waxman DJ; Wagner E; Ogris M
Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
35. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule based delivery systems for alkylating antineoplastic compounds.
Bielawski K; Bielawska A
ChemMedChem; 2008 Apr; 3(4):536-42. PubMed ID: 18157855
[TBL] [Abstract][Full Text] [Related]
37. Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Kakadiya R; Dong H; Lee PC; Kapuriya N; Zhang X; Chou TC; Lee TC; Kapuriya K; Shah A; Su TL
Bioorg Med Chem; 2009 Aug; 17(15):5614-26. PubMed ID: 19576785
[TBL] [Abstract][Full Text] [Related]
38. N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization.
Sykes BM; Atwell GJ; Hogg A; Wilson WR; O'Connor CJ; Denny WA
J Med Chem; 1999 Feb; 42(3):346-55. PubMed ID: 9986704
[TBL] [Abstract][Full Text] [Related]
39. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Wilson WR; Tercel M; Anderson RF; Denny WA
Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
[TBL] [Abstract][Full Text] [Related]
40. Nitro reduction as an electronic switch for bioreductive drug activation.
Siim BG; Denny WA; Wilson WR
Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
